Skip to search formSkip to main contentSkip to account menu

alogliptin

Known as: Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)- pyrimidinyl]methyl]-, 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile, Alogliptinum 
A selective, orally bioavailable, pyrimidinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. In addition to its… 
National Institutes of Health

Related topics

Related topics

16 relations
Dipeptidyl Peptidase 4 Inhibitors [MoA]alogliptin 12.5 MG / Metformin hydrochloride 500 MG Oral Tabletalogliptin 12.5 MG / Metformin hydrochloride 500 MG Oral Tablet [Kazano]alogliptin 25 MG / pioglitazone 30 MG Oral Tablet [Oseni]

Broader (5)

Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsIncretinsPiperidines

Narrower (5)

KazanoNesinaOseniSYR-322

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury.
2016
2016
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
2016
2016
Abstract 16751: Baseline Adiponectin Concentration and Clinical Outcomes Among Patients With Diabetes and Recent Acute Coronary Syndrome in the EXAMINE Trial
Introduction: Adiponectin is a pleiotropic adipocytokine with a strong inverse (protective) association with obesity, diabetes… 
2016
2016
Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes.
Non-alcoholic fatty liver disease (NAFLD) represents one of the most common causes of chronic liver disease worldwide and is… 
Review
2014
Review
2014
Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
2014
2014
The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.
OBJECTIVE Type 2 diabetes mellitus (T2DM) management requires continuous treatment intensification due to progressive decline in… 
2014
2014
Saxagliptin, alogliptin, and cardiovascular outcomes.
The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)–Thrombolysis in Myocardial… 
2013
2013
The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis
Objectives: The potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin improves glycemic control in patients… 
2012
2012
Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization.
Review
2008
Review
2008
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)